Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 22

1.

Direct measurement of hypoxia in a xenograft multiple myeloma model by optical-resolution photoacoustic microscopy.

Imai T, Muz B, Yeh CH, Yao J, Zhang R, Azab AK, Wang L.

Cancer Biol Ther. 2017 Jan 3:1-5. doi: 10.1080/15384047.2016.1276137. [Epub ahead of print]

PMID:
28045569
2.

The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy.

Muz B, de la Puente P, Azab F, Azab AK.

Hypoxia (Auckl). 2015 Dec 11;3:83-92. Review.

3.

A Hypoxia-Targeted Boron Neutron Capture Therapy Agent for the Treatment of Glioma.

Luderer MJ, Muz B, de la Puente P, Chavalmane S, Kapoor V, Marcelo R, Biswas P, Thotala D, Rogers B, Azab AK.

Pharm Res. 2016 Oct;33(10):2530-9. doi: 10.1007/s11095-016-1977-2.

PMID:
27401411
4.

Newly established myeloma-derived stromal cell line MSP-1 supports multiple myeloma proliferation, migration, and adhesion and induces drug resistance more than normal-derived stroma.

de la Puente P, Quan N, Hoo RS, Muz B, Gilson RC, Luderer M, King J, Achilefu S, Salama NN, Vij R, Azab AK.

Haematologica. 2016 Jul;101(7):e307-11. doi: 10.3324/haematol.2016.142190. No abstract available.

5.

MEK inhibitor, TAK-733 reduces proliferation, affects cell cycle and apoptosis, and synergizes with other targeted therapies in multiple myeloma.

de la Puente P, Muz B, Jin A, Azab F, Luderer M, Salama NN, Azab AK.

Blood Cancer J. 2016 Feb 26;6:e399. doi: 10.1038/bcj.2016.7. No abstract available.

6.

Spotlight on ixazomib: potential in the treatment of multiple myeloma.

Muz B, Ghazarian RN, Ou M, Luderer MJ, Kusdono HD, Azab AK.

Drug Des Devel Ther. 2016 Jan 11;10:217-26. doi: 10.2147/DDDT.S93602. Review.

7.

A CD138-independent strategy to detect minimal residual disease and circulating tumour cells in multiple myeloma.

Muz B, de la Puente P, Azab F, Luderer MJ, King J, Vij R, Azab AK.

Br J Haematol. 2016 Apr;173(1):70-81. doi: 10.1111/bjh.13927.

PMID:
26729247
8.

Inhibition of P-Selectin and PSGL-1 Using Humanized Monoclonal Antibodies Increases the Sensitivity of Multiple Myeloma Cells to Bortezomib.

Muz B, Azab F, de la Puente P, Rollins S, Alvarez R, Kawar Z, Azab AK.

Biomed Res Int. 2015;2015:417586. doi: 10.1155/2015/417586.

9.

Tris DBA palladium overcomes hypoxia-mediated drug resistance in multiple myeloma.

de la Puente P, Azab F, Muz B, Luderer M, Arbiser J, Azab AK.

Leuk Lymphoma. 2016 Jul;57(7):1677-86. doi: 10.3109/10428194.2015.1099645.

PMID:
26421357
10.

Identification of ILK as a novel therapeutic target for acute and chronic myeloid leukemia.

de la Puente P, Weisberg E, Muz B, Nonami A, Luderer M, Stone RM, Melo JV, Griffin JD, Azab AK.

Leuk Res. 2015 Sep 9. pii: S0145-2126(15)30377-5. doi: 10.1016/j.leukres.2015.09.005. [Epub ahead of print]

PMID:
26413753
11.

3D tissue-engineered bone marrow as a novel model to study pathophysiology and drug resistance in multiple myeloma.

de la Puente P, Muz B, Gilson RC, Azab F, Luderer M, King J, Achilefu S, Vij R, Azab AK.

Biomaterials. 2015 Dec;73:70-84. doi: 10.1016/j.biomaterials.2015.09.017.

12.

Hypoxia promotes stem cell-like phenotype in multiple myeloma cells.

Muz B, de la Puente P, Azab F, Luderer M, Azab AK.

Blood Cancer J. 2014 Dec 5;4:e262. doi: 10.1038/bcj.2014.82. No abstract available.

13.

Hypoxia promotes dissemination and colonization in new bone marrow niches in Waldenström macroglobulinemia.

Muz B, de la Puente P, Azab F, Ghobrial IM, Azab AK.

Mol Cancer Res. 2015 Feb;13(2):263-72. doi: 10.1158/1541-7786.MCR-14-0150.

14.

The role of hypoxia and exploitation of the hypoxic environment in hematologic malignancies.

Muz B, de la Puente P, Azab F, Luderer M, Azab AK.

Mol Cancer Res. 2014 Oct;12(10):1347-54. doi: 10.1158/1541-7786.MCR-14-0028. Review.

15.

The myeloid-binding peptide adenoviral vector enables multi-organ vascular endothelial gene targeting.

Lu ZH, Kaliberov S, Zhang J, Muz B, Azab AK, Sohn RE, Kaliberova L, Du Y, Curiel DT, Arbeit JM.

Lab Invest. 2014 Aug;94(8):881-92. doi: 10.1038/labinvest.2014.78.

16.

Molecularly targeted therapies in multiple myeloma.

de la Puente P, Muz B, Azab F, Luderer M, Azab AK.

Leuk Res Treatment. 2014;2014:976567. doi: 10.1155/2014/976567. Review.

17.

PI3KCA plays a major role in multiple myeloma and its inhibition with BYL719 decreases proliferation, synergizes with other therapies and overcomes stroma-induced resistance.

Azab F, Vali S, Abraham J, Potter N, Muz B, de la Puente P, Fiala M, Paasch J, Sultana Z, Tyagi A, Abbasi T, Vij R, Azab AK.

Br J Haematol. 2014 Apr;165(1):89-101. doi: 10.1111/bjh.12734.

PMID:
24405121
18.

Cell trafficking of endothelial progenitor cells in tumor progression.

de la Puente P, Muz B, Azab F, Azab AK.

Clin Cancer Res. 2013 Jul 1;19(13):3360-8. doi: 10.1158/1078-0432.CCR-13-0462. Review.

19.

Differential effects of Th1 versus Th2 cytokines in combination with hypoxia on HIFs and angiogenesis in RA.

Larsen H, Muz B, Khong TL, Feldmann M, Paleolog EM.

Arthritis Res Ther. 2012 Aug 6;14(4):R180. doi: 10.1186/ar3934.

20.

Prolyl hydroxylase domain enzyme 2 is the major player in regulating hypoxic responses in rheumatoid arthritis.

Muz B, Larsen H, Madden L, Kiriakidis S, Paleolog EM.

Arthritis Rheum. 2012 Sep;64(9):2856-67. doi: 10.1002/art.34479.

Items per page

Supplemental Content

Support Center